# EDGAR Filing Document

**Accession Number:** 0002012593
**File Stem:** 0000950170-25-087921
**Filing Date:** 2025-6
**Character Count:** 6096
**Document Hash:** fb71365d6b4a3356e84091cde2a634ad
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-25-087921.hdr.sgml**: 20250618

**ACCESSION NUMBER**: 0000950170-25-087921

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 10

**CONFORMED PERIOD OF REPORT**: 20250617

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20250618

**DATE AS OF CHANGE**: 20250618

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Rapport Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0002012593
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 880724208
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42121
- **FILM NUMBER:** 251057344

**BUSINESS ADDRESS:**
- **STREET 1:** 99 HIGH STREET
- **STREET 2:** SUITE 2100
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02110
- **BUSINESS PHONE:** 857-321-8020

**MAIL ADDRESS:**
- **STREET 1:** 99 HIGH STREET
- **STREET 2:** SUITE 2100
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02110

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

## **FORM** 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** June 17, 2025<br>

------

Rapport Therapeutics, Inc.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-42121 | 88-0724208 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| 99 High Street<br>Suite 2100 |  |  |
| Boston**,** Massachusetts |  | 02110 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** (857) 321-8020<br>

Not Applicable

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Common Stock, $0.001 par value per share  | RAPP | The Nasdaq Global Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

## **Item 5.07 Submission of Matters to a Vote of Security Holders.** 
On June 17, 2025, Rapport Therapeutics, Inc. (the "Company") held its 2025 Annual Meeting of Stockholders (the "Annual Meeting"). As of April 21, 2025, the record date for the Annual Meeting, there were 36,497,555 shares of the Company's common stock outstanding and entitled to vote at the Annual Meeting. The Company's stockholders voted on the following matters, which are described in detail in the Company's Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 24, 2025: (i) to elect Reid Huber, Ph.D., John Maraganore, Ph.D., and Wendy B. Young, Ph.D. as Class I directors of the Company, each to serve until the Company's 2028 annual meeting of stockholders, and until his or her respective successor has been duly elected and qualified, or until his or her earlier death, resignation or removal ("Proposal 1"), and (ii) to ratify the appointment of PricewaterhouseCoopers LLP ("PwC") as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 ("Proposal 2").

<u>Proposal 1 - Election of Class I Director Nominees</u>

The Company's stockholders approved the Class I director nominees recommended for election in Proposal 1 at the Annual Meeting. The results of Proposal 1 were as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Class I Director Nominee** | **For** | **Withheld** | **Broker<br>Non-Votes** |
| &nbsp;&nbsp;&nbsp;Reid Huber, Ph.D. | 31146580 | 776312 | 1016695 |
| &nbsp;&nbsp;&nbsp;John Maraganore, Ph.D. | 31222571 | 700321 | 1016695 |
| &nbsp;&nbsp;&nbsp;Wendy B. Young, Ph.D. | 31783990 | 138902 | 1016695 |

---

<u>Proposal 2 - Ratification of Appointment of the Company's Independent Registered Public Accounting Firm</u>

The Company's stockholders ratified the selection of PwC as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. The results of Proposal 2 were as follows:

---

| | | |
|:---|:---|:---|
| **For** | **Against** | **Abstain** |
| 32,804,657 | 112,489 | 22,441 |

---

No other matters were submitted to or voted on by the Company's stockholders at the Annual Meeting.

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | Rapport Therapeutics, Inc.  |
| Date: | June 18, 2025 | By:  | /s/ Troy Ignelzi |
|  |  |  | Troy Ignelzi<br>Chief Financial Officer |

---

------